M-Phase Phosphoprotein 1 (MPP1), a microtubule plus end directed kinesin, is required for the completion of cytokinesis. Previous studies have shown that MPP1 is upregulated in various types of bladder cancer. This article describes inhibitor-screening leading to the identification of a new class of natural product inhibitors of MPP1. Two compounds with structural similarity, norlobaridone (1) and physodic acid (2) were found to inhibit MPP1. Physodic acid is not competitive with ATP, indicating the presence of an allosteric inhibitor-binding pocket. Initial drug-like property screening indicates that physodic acid is more soluble than norlobaridone and has more favorable lipophilicity.
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Molecular motors of the kinesin superfamily move along microtubule (MT) tracks to perform a diverse set of functions from intracellular transport to cell division. 1 Among the 45 different kinesins expressed in humans, the majority is involved in intracellular trafficking processes, whereas about 16 kinesins are implicated in mitosis and cytokinesis. 2, 3 The kinesin-6 family consists of three members, named Mitotic Kinesin-Like Protein 1 (MKLP-1, also known as Kif23), Mitotic Kinesin-Like Protein 2 (MKLP-2, also known as Kif20A, Rabk6, Rabkinesin-6 or Rab6-KIFL) and M-Phase Phosphoprotein 1 (MPP1, also known as Kif20B, KRMP1 or MPHOSPH1), which are predominantly involved in cytokinesis, although report suggest they play non-redundant roles. [3] [4] [5] Members of the kinesin-6 family are unique amongst the kinesin superfamily, because they contain an exceptionally long insertion (8 -10 kDa) of unknown function in the loop L6 region of the motor domain. 6, 7 In contrast to MKLP-1 and MKLP-2 that have been studied intensively, at least in tumor cell lines, there is only very limited information available for the third member of the kinesin-6 family, MPP1. Through genome sequencing projects, MPP1 has been identified in at least 13 eukaryotic species including human, rat, mouse and Xenopus.
Human MPP1 is a slow MTs plus-end-directed molecular motor necessary for the completion of cytokinesis. 3 Particular structural features include the long loop L6 in the motor domain and a particularly long neck-linker region. 3 This protein has been shown to be regulated in vivo by posttranslational modification through phosphorylation in the carboxyl-terminal tail domain at Thr1604 by cdc2 kinase. 8 MPP1 has been reported to interact with the mitotic peptidyl-prolyl isomerase (Pin1) in vivo and that this interaction is mediated through the tail domain of MPP1 and the amino-terminal WW domain of Pin1. Another interacting partner is protein regulator of cytokinesis 1 (PRC1). 9 MPP1's ATPase activity is stimulated by MTs and MPP1 shows MT-bundling activity. In HCT116 colon carcinoma cells, depletion of MPP1 by RNAi leads to defects during cytokinesis, which can result in apoptotic cell death. 3 Interestingly, cell death seems to occur through two different mechanisms: in the first mechanism, the midbody of RNAi treated cells "persists" without abscission and the two physically connected daughter cells undergo apoptosis. In the second mechanism, the midbody regresses leading to the appearance of binucleated cells with subsequent apoptosis. In contrast, in another study, ! 3! in which MPP1 was depleted in HeLa cells, the authors did not detect any significant defects in cytokinesis. 10 The mRNA of MPP1 has been shown to be significantly upregulated in bladder cancer (and in a variety of bladder cancer tumor cell lines) as well as large B cell lymphoma. 9, 11 In total, MPP1's interaction with PRC1 and its subsequent implication in bladder carcinogenesis makes MPP1 a potential target for bladder cancer drug development. 12 2-Phenylquinoxalines 13 have been reported as small molecule inhibitors of MPP1 but the patent has subsequently been withdrawn. In this project small molecule libraries from the NCI were screened for the inhibition of the ATPase activity of human MPP1.
The aim of this study was to identify novel MPP1-specific inhibitors that can be used as chemical probes for studying MPP1 biology and as potential lead compounds for drug development. In this paper the recombinant expression, purification and biochemical characterization of two human MPP1 motor domain constructs are described. It also reports the discovery and characterization of an MPP1-specific inhibitor, originally isolated from lichens, known as depsidones that was identified using an in vitro inhibitor screening assay. MPP1-inhibitor interaction and investigation of the effect on different tumor cell lines including bladder, colon, pancreatic and leukemia cell lines were subsequently characterized. In addition, some basic drug-like properties of the MPP1specific inhibitor were also characterized. In conclusion this paper describes the identification and characterization of an MPP1-specific inhibitor ( Figure 1A and 1B) that can be used to study the biochemical and structural features of human MPP1. However, further development is necessary to improve its physico-chemical properties and potency.
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RESULTS AND DISCUSSION
Characterization of MPP1 Motor Domain Constructs.
Human MPP1 is a protein of 1853 residues (Figure 2A ). It contains a short N-terminal sequence of unknown function preceding the motor domain (aa 1 to 56), followed by the motor domain (aa 56 to 491) which includes a large loop L6 insertion (aa 186 to 262) ( Figure 2B ), a particularly long discontinuous coiled coil region (aa 568 to 1600) and a C-terminal tail domain (aa 1602 to 1853) ( Figure 2A ). Two MPP1 constructs, coding for residues 2 to 477, which also include the small N-terminal domain (residues 2 to 56) preceding the motor domain and residues 57 to 491 (subsequently named MPP1 2-477 throughout the manuscript) and a protein covering the entire MPP1 motor domain (named MPP1 57-491 ) but lacking the first 56 residues, were cloned into an E. coli expression vector and were expressed and purified to homogeneity. Mass spectrometry finger print analyses with sequence coverage of 56% and 77% respectively confirmed that the two purified proteins were indeed human MPP1. Gel filtration analysis revealed that MPP1 2-477 (51 kDa) and MPP1 57-491 (43 kDa) are both monomeric in solution (data not shown).
To optimize and miniaturize the experimental conditions for inhibitor screening and subsequent biochemical assays, the basic kinetic parameters of MPP1 2-477 and MPP1 57-491 were first investigated ( Table 1 and Figure 3 ). We used two different constructs, one including the small 56 residues long N-terminal domain adjacent to the motor domain and the second construct lacking this domain ( Figure 2A ). Our aim was to identify whether the N-terminal small domain would have an effect on the overall kinetic properties of the MPP1 motor domain and whether this N-terminal domain would be involved in inhibitor binding or not.
Determination of the salt-dependence of the basal ATPase activity was performed by measuring the k cat in the presence of increasing NaCl concentrations. The activity decreases with increasing salt concentration indicating that the basal MPP1 ATPase activity is best measured in the absence of salt for both motor domain constructs ( Figure   3A ). The basal ATPase activity in the presence of increasing ATP concentrations, in the absence of salt led to a maximum k cat of 0.016 ± 0.001 s -1 with a K M,ATP of 68.5 ± 16 µM for MPP1 and the k cat for MPP1 57-491 is 0.010 ± 0.001 s -1 with a K M,ATP of 128 ± 2.1 ( Figure 3B ). Subsequently, MT-stimulated k cat as well as the K M,ATP and K 0.5,MT in the Figure 3D ). We conclude from the above data that the absence or presence of the small N-terminal head domain preceeding the motor domain does not significantly affect the kinetic properties of MPP1. Therefore, we decided to use MPP1 57-491 , which could be expressed in larger amounts than MPP1 2-477 for further inhibitor screening.
Inhibitor Screening and Hit Identification. Based on these results, initial screening of MPP1 57-491 for inhibitors was conducted by observing the inhibition of the basal ATPase activity in the absence of salt and in the presence of 1 mM Mg 2+ ATP, using several small molecule libraries from the NCI including the mechanistic, the structural diversity and the natural product sets. One initial hit was the depsidone norlobaridone (1), a natural product originally isolated from Xanthoparmelia conspersa and X. scabrosa ( Figure 1 ). 14 To verify the initial hit obtained in the library the powder was obtained from the NCI/NIH and its activity MPP1 57-491 was quantified. Norlobaridone (1) inhibits the basal MPP1 ATPase activity with an IC 50 of 18.7 ± 2.6 µM and the MT-stimulated ATPase activity with an IC 50 of 24.4 ± 3.5 µM indicating that it is a weak inhibitor of MPP1. An analogue, physodic acid (2), tested thereafter was more active than 1 inhibiting the basal and MT-stimulated ATPase activities with IC 50 values of 9.9 ± 1.1 µM and 5.8 ± 0.9 µM, respectively ( Figure 4 ). To exclude the possibility of aggregation based inhibition 15 , the inhibition of the basal ATPase activity of both 1 and 2 were measured in the presence of 0.1% Tween-20 to reduce compound aggregation. The IC 50 values obtained for both the inhibitors were similar to those obtained without detergent (data not shown). Interestingly, MPP1 , which contains the small N-terminal domain preceding the motor domain, is inhibited by both depsidones to a larger extend than the shorter MPP1 construct ( Table 2 ). The depsidone variolaric acid (3), which contains an additional five-membered ring system but lacks the alkyl chains, is inactive. 1 and 2 ! 6! contain two alkyl substituents, which might contribute towards their activity against MPP1 ATPase activity.
The compounds were then tested in proliferation assays using HCT116 (colon), Bx-PC-3 (pancreatic), K562 (leukemia) and J82 as well as UM-UC-3 (both bladder cancer) cell lines ( Table 3 ). The well-known Eg5 inhibitor STLC (4) was used as a control. Interestingly, 1 and 2, displayed a measurable effect in the panel of cell lines tested with GI 50 values ranging between 31.8 to 48.3 µM. 3 did not show any measurable effects in the concentration range tested.
Determination of the Type of Inhibition for MPP1 in the Absence or Prese-
nce of MTs. The type of inhibition for 2, was then determined for the more potent analogue. In the absence of MTs, 2 is an un-competitive inhibitor of MPP1 with respect to ATP ( Figure 5A ), as indicated by decreasing V max and K m values. In the presence of MTs, 2 is a mixed inhibitor (a special case of non-competitive inhibition) of MPP1 with respect to ATP ( Figure 5B ) as observed by an increase in apparaent K m but a decrease in the apparent V max when the K m,ATP is measured at increasing concentrations of 2. On the other hand 2 is non-competitive with respect to MTs ( Figure 5C ) as the apparent K m remains the same whereas V max decreases with increasing inhibitor concentrations.
Determining the Specificity of Physodic acid (2) within the Kinesin
Superfamily. The specificity of 2 was measured for MPP1 by investigating the possible inhibition of the ATPase activity of human kinesins from different subfamilies ( Table 4 ).
2 was specific for human MPP1 as it did not significantly inhibit any other mitotic kinesins of the kinesin-6 family or other kinesins involved in mitosis or cytokinesis, for example Eg5 (kinesin-5) 16 , Kif15 17 (kinesin-12), or MKLP-2 18 /MKLP-1 (kinesin-6).
Compound 2 also did not inhibit the activity of two kinesins involved in intracellular transport, Kif7 19 /Kif27 (kinesin-7) and Kif5a/Kif5b (kinesin-1). Partial inhibition of between 40% and 50% at 200 µM for Kif4 and Kif9 were observed, for which no IC 50 value could be calculated. The compound also showed partial inhibition of between 60% and 70% for both the basal and MT-stimulated ATPase activity of the kinetochore motor CENP-E with IC 50 values of 29.6 ± 12.7 µM and 91.4 ± 31.0 µM, respectively.
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Profiling of Drug-Like Properties. The determination of basic drug-like
properties provided important insights into ADME characteristics of 1 and 2 ( Table 5 ).
Both compounds show pH-dependent solubility, which rises with increasing pH. Whereas 1 shows only partial solubility at pH 7.4, 2 has good solubility probably due to the presence of an additional carboxylic acid group. The logD 7.4 (the distribution coefficient at a pH of 7.4) of 3.0 for 2 is slightly more favorable than for norlobaridone (logD 7.4 = 3.5). In PAMPA assays, which investigate passive diffusion, 1 showed some passive permeability whereas 2 did not display any permeability. The bi-directional Caco-2 permeability assay was used to determine the compound efflux ratio. Whereas 2 did not give satisfactory results, the efflux ration for 1 was 0.51 indicating that no drug efflux occurs. Subsequent testing of both compounds in human and mouse microsomal stability assays showed high clearance in human and mouse microsomal stability assays with halflife times of only 3.5 and 4.5 min in human microsomes and 3.1 min and 22.5 min in mouse microsomes for 1 and 2, respectively. In both human and mouse microsomal stability assays, physodic acid showed low values in the control without cofactor, which indicates either chemical instability or non-cofactor dependent enzymatic degradation.
Compound 2 was therefore tested in chemical stability assays and was shown to be stable, although it showed some minor unspecific binding to polypropylene. In addition, assays performed in the absence of microsomes for both compounds indicated that they were chemically stable. This points to a non-NADPH-dependent enzymatic process in the microsomes, that also contributes to some clearance, but which was not investigated further. To further investigate the high clearance observed for depsidones compound 2 was incubated with human liver microsomes and the resulting metabolites identified by mass spectrometry. Three metabolic pathways were found by LC-MS and the relationship of the products to 1 was determined by their collision induced mass spectra (see the Supplementary Material Section for details). They were hydrolysis of the lactone ring (- 27,28 , 28 and the most promising compound, ARRY-520, has proven effective in refractory and relapsed multiple myeloma in combination with a proteasome inhibitor. One potential novel candidate is MPP1 from the kinesin-6 family. This unusual motor protein has previously been shown to move towards the plus-end of MTs and is involved in cytokinesis. 3 
MPP1
has also been reported to be phosphorylated during mitosis at its C-terminus, which is crucial for its role in cytokinesis. 8 Importantly, previous literature also suggests the importance of MPP1 overexpression in progressive and invasive forms of bladder cancer. 9 These initial findings suggest that MPP1 may serve as a potential drug candidate for targeting bladder cancer and specific chemical probes against MPP1 may serve to further validate this early hypothesis.
A patent 13 reported specific MPP1 inhibitors known as 2-phenylquinoxalines (6) ( Figure 1 ). There was a marked phenotype of bineculated cells in BSC-1 (African green monkey) cells treated with these inhibitors, but unfortunately, the patent was later withdrawn.
In order to identify novel inhibitors of MPP1, two MPP1 motor domains were first cloned, expressed and purified with subsequent characterization of their kinetic parameters ( Table 1 ). The analysis confirmed similarities with other motor domain from different kinesins like Eg5 29, 30 , Kif15 17 and Ncd 30 . Thereafter, in order to identify potential inhibitors of MPP1, in vitro screening using previously established procedures was performed. 31 Reported here is the identification and initial characterization of two closely related natural product inhibitors of MPP1, 1 and 2 acid from a class of compounds known as depsidones derived from lichens.
Having demonstrated that 2 is a low micro molar inhibitor of MPP1, the type of ! 9! inhibition was characterized thereafter. The results show that 2 is a un-competitive inhibitor with respect to ATP under basal and a mixed inhibitor when measured in the presence of MTs and is a non-competitive inhibitor with respect to MTs. Since depsidones do not compete with ATP or MTs, MPP1 must also contain at least one allosteric inhibitor-binding pocket, as observed in other kinesins for example Eg5, CENP-E and KifC1.
Lichens are symbiotic organisms composed of algae or cyanobacteria and fungi.
Morethan 1,000 compounds have been isolated from different lichens, which have been estimated to comprise almost 20,000 species. Many of the secondary metabolites that have been identified so far are unique to lichens. Lichen metabolites have been shown to possess a range of interesting biological properties including antioxidant, antimicrobial, antiherbivore and insecticidal activities. 32 Several natural products from lichens have been shown to possess cytotoxic activity 33 and for a few isolated lichen metabolites growth inhibition and apoptotic cell death has been reported. 34, 35 One interesting class of lichen compounds is represented by depsidones containing the dibenzodioxepinone scaffold ( Figure 1 ) and for which a number of structurally related derivatives have been isolated and characterized from a variety of lichen species. 36 Cytotoxic activity has been observed for several chlorinated depsidones 35 and botryosphaerones. 37 In most cases, the biological targets that are inhibited are unknown. Therefore, the identification of the target(s) for these compounds will open the way of their use as chemical probes to study the function of these proteins, to further validate their potential as therapeutic targets and in the best case improve their chemical scaffolds for drug development. Compound 4 has recently been shown to inhibit tubulin polymerization 38 and MPP1 is a novel cytoskeletal protein target to be identified for the class of compounds known as depsidones. A structurally related depsidone, Corynesidone A (Figure 1) , extracted from the fungus Corynespora cassicola L36, is a known aromatase inhibitor. 39 In this study it was also observed that in cell based assays, 2 is effective with GI 50 values of around 30 µM in bladder cancer cell lines. Although cell-based activity is only weak, this is in line with previous finding where MPP1 has been found to be overexpressed in various bladder cancer cell lines. Though the initial compounds display low potency in tumor cell lines, further development, particularly with regard to ! 10! improving the metabolic liabilities of the compounds and optimizing their drug-like properties, may increase their efficacy. A major problem is the lack of metabolic stability of both depsidones with half lifes of only several minutes in human and mouse microsomal stability assays ( Table 5 ). The subsequent metabolite identification study for compound 2 revealed the Achilles' heel of this type of compound, which will have to be taken into account for further optimization: the major metabolites originated from hydrolysis of the lactone ring metabolite M1, or hydroxylation of the alkyl chain (C 5 H 11 to C 5 H 10 OH) metabolite M2, and finally cleavage of the ether bond of metabolite M1 to give M3.
In conclusion, further optimization of potency coupled with efficacy in tumor cell lines to study MPP1 function will require the substitution and/or stabilization of the labile lactone ring and removal or shortening of the alkyl chains, if these substituents are not required for activity against MPP1. Reducing the length of the alkyl chains would also have the additional advantage of reducing lipophilicity (clogP) and increase solubility of the analogues in aqueous solution.
In summary, a low micromolar natural product inhibitor, physodic acid (2), has been reported here that targets MPP1 identified using an in vitro screening method. The inhibitor is specific for MPP1 compared to other kinesins but displays some drug like property liabilities such as high metabolic clearance and low cell permeability. This novel MPP1 inhibitor can be used as a chemical probe to study MPP1 either biochemically, biophysically or structurally. In particular a crystal structure of the depsidone-MPP1-Mg 2+ ADP ternary complex would be useful to understand the interactions in molecular detail. Further improvement of the scaffold will focus on studying analogues of available depsidones to identify analogues with improved potency and drug-like properties. 
Initial Drug-Like Property Profiling and Metabolite Identification.
Turbidimetric solubility, log D7.4 , and human as well as mouse microsomal stability were determined as previously described. 41 PAMPA, Caco-2 and chemical stability assays were carried out at Cyprotex according to internal protocols, including all necessary controls. where, (ε NADH corresponds to the molar extinction coefficient of NADH (6220 ΔA/mol/cm), ΔA/min is the absorbance decrease at 340 nm per min, and C enzyme is the molar concentration of MPP1 used in the assay. The factor 2 is a correcting factor taking into account the length of the optical path in the 96-well plate, normalized to a path of 1 cm. The IC 50 values for the inhibition of the basal and MT-stimulated ATPase activities of MPP1 were calculated for depsidones analogues at concentrations ranging from 0 µM to 200 µM.
Cloning, Expression and Purification of
Determination of the Type of Inhibition of Physodic Acid for MPP1 in the
Absence and Presence of MTs. The type of inhibition for the depsidones in the absence and presence of MTs was determined based on the steady state ATPase measurements as described above. Compound 2 was the more potent compound and was selected for these assays. The V max and K m of ATP in the absence and presence of MTs and for MTs (at a constant ATP concentration) were measured to decipher the type of inhibition. For the determination of the type of inhibition with respect to ATP in the absence of MTs, ATP was used at a concentration range from 0 to 2 mM for each individual inhibitor concentration at 0, 1, 5, 10 and 20 µM.
The type of inhibition with respect to ATP in the presence of MTs was determin- Experimental procedures were as previously described. 44 Briefly, cells were seeded in triplicate in 96-well assay plates at 1.250 cells (HCT116), 2.000 cells (J82, UM-UC-3), or 5.000 cells (K562) per well in 100 µL of the respective growth medium. Medium blanks (without any cells) and cell blanks (without any inhibitors) for every cell line were also prepared. On the next day, inhibitors were added with a starting concentration of 100 µM in a 3-fold serial dilution series. After 72 h post inhibitor addition, 10% Alamar Blue (Invitrogen, Paisley, UK) was added and depending on the cell line, 2-12 h later the absorbance was measured at 570 and 600 nm.
All values were corrected for the absorbance of the medium blank and the corrected cell blanks were set to 100%. Calculations for determining the relative proliferation were performed using equations described in the manufacturer's manual. Finally, the EC 50 values were determined using a sigmoidal dose-response fitting (variable slope) with has been shown to inhibit MPP1, although the patent has been withdrawn. 
